Home › Langerhans-Cell Histiocytosis › New York
Langerhans-Cell Histiocytosis clinical trials in New York
3 studies for Langerhans-Cell Histiocytosis are looking for participants at sites in New York.
Cities in New York
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
- and 7 more
RecruitingPhase 2
180 Days – 22 Years · All sexes · Updated Oct 2, 2026 · NCT05828069Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
- Memorial Sloan Kettering Cancer Center, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 8, 2026 · NCT03329274Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
All ages · All sexes · Updated Sep 18, 2025 · NCT04079179From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.